araag2/HINT huggingface dataset:
Clinical trial NCT00179712 (phase 1/phase 2, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cc-5013, topotecan
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects must understand and voluntarily sign an informed consent document.

          2. Age >or = to 18 years at the time of signing informed consent form.

          3. Subjects must be able to adhere to the study visit schedule and other protocol
             requirements.

          4. Histological or cytological documentation of advanced ovarian or primary peritoneal
             carcinoma.

          5. Radiographic or clinical evidence of measurable metastatic advanced ovarian or primary
             peritoneal carcinoma. Subjects must have measurable disease at least 2 cm in diameter.

          6. Subjects must have been treated and progressed following chemotherapy which includes
             platinum and paclitaxel.

          7. ECOG performance status of 0 or 1 (Appendix I: ECOG Performance Status Scale).

        Exclusion Criteria:

          1. Any of the following laboratory abnormalities:

               1. Absolute neutrophil count (ANC) <1,500 cells/mm3 (1.5 x 109/L)

               2. Platelet count <100,000 cells/mm3 (100 x 109/L)

               3. Serum creatinine >1.5 mg/dL (133 mmol/L)

               4. Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)

               5. Serum total bilirubin >2.0 mg/dL (34 mmol/L)

          2. Any serious medical condition or psychiatric illness that places the subject at an
             unacceptable risk for study participation or would prevent the subject from signing
             the informed consent.

          3. Prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma
             in situ of the breast) unless the subject has been free of disease for > 1 year.

          4. Known brain or leptomeningeal disease (CT scan or MRI of the brain required only in
             case of clinical suspicion of central nervous system involvement).

          5. More than 1 prior chemotherapy regimen. However, subjects with platinum sensitive
             disease (i.e., subjects who fail a platinum containing regimen at least six months
             after completing the regimen) who are retreated with a platinum containing regimen are
             eligible.

          6. Concurrent use of any other anti-cancer agents.

          7. Any prior use of lenalidomide.

          8. Prior > or = to grade 3 (see Appendix III) rash or any desquamating (blistering) rash
             while taking thalidomide.

          9. Prior . Or = to grade 3 (see Appendix III) allergic reaction/hypersensitivity to
             thalidomide.

         10. Use of any standard or experimental anti-cancer drug therapy within 28 days of the
             initiation of study drug therapy.

         11. Known active Hepatitis C.
Clinical trial NCT00578370 (phase 1/phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ciclosporin 0.5% (formulation 01b), ciclosporin 1.5% (formulation 02b), 0.1% betamethasone, 0.005% calcipotriol, formulation 00b
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with chronic plaque type psoriasis

          -  Sexually active females of childbearing potential should either be surgically sterile
             (hysterectomy or tubal ligation), or should use a highly effective medically accepted
             contraceptive regimen

        Exclusion Criteria:

          -  Local treatment with antipsoriatics (except for salicylic acid in vaseline) in the 4
             weeks preceding and during the study (corticosteroids 8 weeks)

          -  Systemic treatment with antipsoriatics or therapy with PUVA, selected ultraviolet
             photo therapy in the three months preceding and during the study

          -  Treatment with systemic or locally acting medications which might counter or influence
             the study aim

          -  Previous therapy with methotrexate over many years

          -  Therapy with nephrotoxic medication

          -  Therapy with digoxin, colchicin and statins

          -  Medications which might influence the potassium metabolism

          -  Subjects with known dysfunction of the calcium metabolism

          -  Subjects with increased uric acid or potassium serum levels

          -  Erythrodermic psoriasis, psoriasis punctata and pustular psoriasis or extended chronic
             stationary forms of psoriasis

          -  Subjects with acute virus infection

          -  Subjects with acne, anogenital pruritus, rosacea, perioral dermatitis, specific skin
             problems (skin tuberculosis, luetic skin diseases), vaccination reactions, skin
             infections caused by bacteria or viruses

          -  Symptoms of a clinically significant illness that may influence the outcome of the
             study in the four weeks before and during the study
Clinical trial NCT00483262 (phase 1/phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: cci-779, bortezomib
SMILES: OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Must have received prior therapy for their myeloma and have relapsed and/or
             relapsed/refractory multiple myeloma

          -  Monoclonal protein in the serum of greater than or equal to 1 gm/dL or monoclonal
             light chain in the urine protein electrophoresis of greater than or equal to 200mg/24
             hours, or measurable light chains by free light chain assay of greater than or equal
             to 10mg/dl, or measurable plasmacytoma

          -  ECOG Performance Status 0, 1 or 2

          -  Laboratory values as outlined in the protocol

        Exclusion Criteria:

          -  Uncontrolled infection

          -  Cytotoxic chemotherapy less than 2 weeks, or biologic therapy less than 2 weeks, or
             corticosteroids less than 2 weeks prior to registration. Patients may be receiving
             chronic corticosteroids if they are being given for disorders other than myeloma.

          -  Pregnant or nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception

          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
             considered investigational within 14 days before enrollment

          -  Known to be HIV positive

          -  Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV
             hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities

          -  Hypersensitivity to bortezomib, boron or mannitol

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical trial

          -  Patients who may need or are receiving live vaccines for immunization
Clinical trial NCT00002863 (phase 1, status: terminated)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    insufficient accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Biopsy-proven soft tissue sarcoma (STS) of the extremity Review by
        Pathology Department of the University of Southern California CT or MRI required prior to
        biopsy Disease in one of the following categories: High-grade tumor Low-grade tumor at high
        risk for local recurrence, i.e.: Adjacent to bone or vital neurovascular structures and
        able to be removed with a minimal surgical margin (i.e., plane of dissection goes through
        reactive zone of tumor) Lesion more than 5 cm in diameter The following tumors exclude:
        Primary sarcoma of the bone Metastatic carcinoma STS of the head and neck Visceral STS,
        e.g., breast, uterus, spermatic cord, mediastinum chest wall STS of the pelvis or
        retroperitoneum

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: WBC
        at least 3,000 Platelets at least 75,000 Hemoglobin at least 9 g/Dl Hepatic: Bilirubin no
        greater than 1.5 mg/dL AST/ALT no greater than 2.5 times normal Renal: Not specified Other:
        No concurrent disease that renders patient medically or psychologically unable to tolerate
        treatment

        PRIOR CONCURRENT THERAPY: At least 30 days since therapy for sarcoma
Clinical trial NCT01571388 (phase 1, status: completed)
Conditions: healthy, otherwise healthy volunteers with mild or moderate hepatic dysfunction
ICD codes: Z76.3, Z76.2
Drugs: dacomitinib, dacomitinib, dacomitinib
SMILES: COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and/or female subjects of non-childbearing potential between the ages of
             18 years of age to <75 years of age. Healthy is defined as no clinically relevant
             abnormalities identified by a detailed medical history, full physical examination,
             including blood pressure and pulse rate measurement, 12-lead ECG and clinical
             laboratory tests. Liver function tests, albumin and prothrombin time must be within
             normal range.

          -  Body Mass Index (BMI) of 18 to 35 kg/m2;

          -  An informed consent document signed and dated by the subject.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

          -  Subjects in the normal hepatic function group (Group 1): No known or suspected hepatic
             impairment.

          -  For subjects in the hepatic impairment groups (Groups 2 and 3):

               -  Should satisfy the criteria for Class A or B of the modified Child-Pugh
                  classification

               -  A diagnosis of hepatic dysfunction due to hepatocellular disease (and not
                  secondary to any acute ongoing hepatocellular process) documented by medical
                  history, physical examination, liver biopsy, hepatic ultrasound, CT scan, or MRI.

               -  Stable hepatic impairment, defined as no clinically significant change in disease
                  status within the last 30 days, as documented by the subject's recent medical
                  history

               -  Must be on a stable dose of medication and/or treatment regimen.

        Exclusion Criteria:

          -  Any condition possibly affecting drug absorption (eg, gastrectomy, chronic diarrhea,
             rapid transit).

          -  A positive urine drug screen.

          -  Females of childbearing potential, including those with tubal ligation. [To be
             considered for enrollment, women of at least 45 years of age who are postmenopausal
             (defined as being amenorrheic for at least 2 years) must have confirmatory FSH test
             results at screening].

          -  In addition, subjects in the hepatic impairment groups (Groups 2 and 3) presenting
             with any of the following will not be included in the trial:

               -  Hepatic carcinoma and hepatorenal syndrome or life expectancy <1 year.

               -  Undergone porta-caval shunt surgery.

               -  History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers
                  less than one month prior to study entry.
Clinical trial NCT00207116 (phase 1, status: completed)
Conditions: carcinoma, non-small-cell lung, neoplasm metastasis
ICD codes: D02.20, D02.21, D02.22, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Measurable disease tumor available for biopsies

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Known or documented brain metastases prior to Cetuximab therapy
Clinical trial NCT00151320 (phase 1/phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bortezomib, chop, rituximab
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of diffuse large B cell or mantle cell
             Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles. For mantle cell:
             CD5(+), CD19(+) or CD20(+), cyclin D1(+), CD23(-) and CD10(-).

          -  Patient has not received any prior anti-cancer therapy for lymphoma

          -  Tumor tissue confirmed to express the CD20 antigen

          -  Available frozen tumor tissue(rebiopsy if needed)

          -  Patient has measurable disease as defined by a tumor mass > 1.5 cm

          -  Patient has Stage II, III, or IV disease

          -  Age > 18 years

          -  Absolute granulocyte count > 1000 cells/mm3

          -  Platelet count > 50,000 cells/mm3

          -  Creatinine < 2.0 x ULN

          -  Total bilirubin < 2.0 x ULN

        Exclusion Criteria:

          -  Known central nervous system (CNS) involvement by lymphoma

          -  Known HIV disease

          -  Patient is pregnant or nursing

          -  Patient has had major surgery within the last 3 weeks

          -  Patient is receiving other investigational drugs

          -  Known peripheral neuropathy > Grade 2
Clinical trial NCT00469937 (phase 1, status: terminated)
Conditions: brain and central nervous system tumors, cognitive/functional effects, neurotoxicity, solid tumor
ICD codes: G92.00, G92.01, G92.02, G92.03, G92.04, G92.05
Drugs: lithium carbonate
SMILES: [Li+]
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histopathologically confirmed extracranial primary malignancy

               -  Multiple (i.e., > 3) brain metastases OR < 3 metastases with at least 1
                  metastasis > 4.0 cm in diameter

               -  Not eligible for radiosurgery

          -  No requirement for immediate whole-brain radiotherapy

          -  No metastases to the midbrain or brainstem

        Exclusion Criteria:

          -  Zubrod performance status 0-2

          -  Life expectancy ≥ 8 weeks

          -  Platelet count > 100,000/mm^3

          -  ANC > 1,500/mm^3

          -  Hemoglobin ≥ 10 g/dL

          -  BUN < 25 mg/dL

          -  Creatinine < 1.5 mg/dL

          -  Bilirubin < 1.5 mg/dL

          -  ALT ≤ 2 times normal

          -  Sodium > 136 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Neurologically stable

               -  No seizure disorders or seizures due to brain metastases

          -  No medical illnesses or psychiatric conditions that would preclude completion of study
             treatment

          -  No sensory neuropathy ≥ grade 2

          -  No bipolar disorder

          -  No thyroid disease

          -  No QTc interval prolongation

        PRIOR CONCURRENT THERAPY:

          -  More than 2 weeks since prior and no concurrent chemotherapy

          -  At least 2 weeks since prior and no concurrent NSAIDs, angiotensin-converting enzyme
             inhibitors (e.g., enalapril or captopril), calcium channel blockers, diuretics,
             selective cyclooxygenase-2 inhibitors, acetazolamide, urea, xanthine, or alkalinizing
             agents (e.g., sodium bicarbonate)

          -  No prior radiotherapy to the head and neck area

          -  No prior radiosurgery

          -  No concurrent radiotherapy to other sites

          -  No concurrent anticonvulsants due to brain metastases

          -  No concurrent psychoactive drugs

          -  No concurrent thyroid medications

          -  No concurrent amifostine
Clinical trial NCT03202875 (phase 1, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: sar341402, insulin aspart, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria :

          -  Male or female subjects with diabetes mellitus type 1 for more than one year.

          -  Total insulin dose of < 1.2 U/kg/day.

          -  Fasting negative serum C-peptide (< 0.3 nmol/L).

          -  Glycohemoglobin (HbA1c) ≤ 9%.

          -  Stable insulin regimen for at least 2 months prior to study.

          -  Normal findings in medical history and physical examination (cardiovascular system,
             chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and
             musculo-skeletal system), vital signs, electrocardiogram (ECG) and safety lab.

        Exclusion criteria:

          -  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic (apart from diabetes mellitus type 1),
             hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular,
             or infectious disease, or signs of acute illness.

          -  More than one episode of severe hypoglycemia with seizure, coma or requiring
             assistance of another person during the past 6 months.

          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice
             a month.

          -  Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or
             asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20
             mmHg within 3 minutes when changing from supine to standing position.

          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician.

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the clinical study protocol.

          -  Any medication (including St John's Wort) within 14 days before inclusion or within 5
             times the elimination half-life or pharmacodynamic half-life of the medication, with
             the exception of insulins, thyroid hormones, lipid-lowering and antihypertensive drugs
             and if female with the exception of hormonal contraception or menopausal hormone
             replacement therapy; any vaccination within the last 28 days.

          -  Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen,
             anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and
             2 antibodies (anti-HIV1 and anti HIV2 Ab.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01645215 (phase 1, status: completed)
Conditions: tumor
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: fruquintinib
SMILES: CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 and ≤ 70 years of age

          -  Histological or cytological confirmed solid malignant tumor

          -  ECOG performance status of 0-1

          -  Standard regimen failed or no standard regimen available

          -  Life expectancy of more than 12 weeks

          -  LVEF ≥ 50%

          -  Duration from the last therapy is more than 4 weeks for operation or radiotherapy;
             more than 4 weeks for prior systemic treatment

          -  Adequate hepatic, renal, heart, and hematologic functions (platelets > 80 × 109/L,
             neutrophil > 1.5 × 109/L, hemoglobin > 90g/dl ,serum creatinine within upper limit of
             normal(ULN), total bilirubin and serum transaminase within upper limit of normal(ULN),
             and PT, APTT, TT, Fbg normal

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

          -  signed and dated informed consent.Willingness and ability to comply with scheduled
             visits, treatment plans, laboratory tests, and other study procedure

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Any factors that influence the usage of oral administration

          -  Evidence of uncontrolled CNS metastasis

          -  Intercurrence with one of the following: non-controlled hypertension, coronary artery
             disease, arrhythmia and heart failure

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial

          -  Previous treatment with VEGF/VEGFR inhibition

          -  Disability of serious uncontrolled intercurrence infection

          -  Proteinuria ≥ 2+

          -  Uncontrolled hemorrhage in GI

          -  Within 12 months before the first treatment occurs artery/venous thromboembolic
             events, such as cerebral vascular accident (including transient ischemic attack) etc.

          -  Within 6 months before the first treatment occurs acute myocardial infarction, acute
             coronary syndrome or CABG

          -  Bone fracture or wounds that was not cured for a long time

          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy
Clinical trial NCT00127829 (phase 1, status: completed)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed solid tumor refractory to conventional treatment or whom no
             standard of treatment exists

          -  Life expectancy of > 12 weeks

          -  World Health Organization (WHO) performance status of < 2

        Exclusion Criteria:

          -  Known severe hypersensitivity to gefitinib or any of the excipients of this product

          -  Less than 4 weeks since completion of prior chemotherapy or radiation therapy (except
             nitrosoureas or mitomycin-C which must have a wash out period of 6 weeks)

          -  Incomplete healing from previous oncologic or other major surgery